Navigation Links
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
Date:12/5/2007

stitutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical rebates and reimbursement, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, difficulties and delays in product development, manufacturing or sales, patent positions and the ultimate outcome of any litigation matter, including whether Apotex will prevail in its appeal of the District court's decision in the PLAVIX(R) patent litigation. These factors also include the company's ability to execute successfully its strategic plans, including its Productivity Transformation Initiative and any significant acquisitions and divestitures, the expiration of patents on certain other products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, furnished to and filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether a
'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
5. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
10. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014  Atlas Venture, an early ... and technology innovation, today announced that Jason Rhodes ... EPZM ), is joining the firm,s life ... 2014. At Atlas, Rhodes will work closely ... He brings an accomplished record in company creation, deal ...
(Date:9/29/2014)... , September 29, 2014 ... greater competition to transform network connectivity as customers ... ProLabs , the leading independent ... today the findings of their survey conducted at ... with top optical communications professionals from across the ...
(Date:9/29/2014)... 2014 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that the U.S. ... Orphan Drug Designations for the Company,s lead drug ... small cell lung cancer and ovarian cancer.  Aldoxorubicin ... agent, doxorubicin. "The FDA,s decision to ...
(Date:9/28/2014)... Modality Solutions, a ... for highly regulated industries, is pleased to announce ... Advantage Transport Simulation Laboratoryâ„¢ software at the 12th ... Global Forum in Boston, September 29 through October ... lab software on October 2, day two of ...
Breaking Biology Technology:Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team 2End of an Era: OEM Dominance - Could it be a Thing of the Past? 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3
... terrorism scenarios that raise the most concern are ... reason, technology that can effectively detect smuggled radioactive ... To support the nation,s nuclear-surveillance capabilities, researchers at ... ways to enhance the radiation-detection devices used at ...
... 2012  Neogen Corporation (Nasdaq: NEOG ) announced today ... genomics business from Merial Limited. Igenity will operate as a ... place in the worldwide animal genomics business. ... several other countries for nine years, and already has provided ...
... (NASDAQ: SSRX ) ("3SBio" or "the Company"), ... manufacturing and marketing biopharmaceutical products, today announced that it ... for the fiscal year ended December 31, 2011 with ... 2012. The annual report on Form 20-F, which contains ...
Cached Biology Technology:Novel radiation surveillance technology could help thwart nuclear terrorism 2Novel radiation surveillance technology could help thwart nuclear terrorism 3Novel radiation surveillance technology could help thwart nuclear terrorism 4Neogen acquires Igenity from Merial 2Neogen acquires Igenity from Merial 3
(Date:9/29/2014)... found that a combination of a real-time feedback system ... of residence resulted in a reduction of 37% in ... were 1360.49 kWh, which is equivalent to a reduction ... weeks. , In contrast, another eight halls, exposed ... alert, resulted in saw a 3.5% reduction in energy ...
(Date:9/29/2014)... , Canda, September 29, 2014 ... Such as UID Coupled with Increasing Security Concerns ... India is one ... witnessing increasing adoption of biometrics systems, majorly in ... e-drivers, NREGA, etc. Fingerprint modality based biometrics dominates ...
(Date:9/29/2014)... Droplets are simple spheres of fluid, not normally considered ... researchers have made droplets of alcohol move through water. ... etc.,To be able to move on your own ... in living organisms. But also non-living entities can be ... Institute of Chemical Technology in Prague, Czech Republic. , ...
Breaking Biology News(10 mins):India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3Scientists make droplets move on their own 2
... Dr. Zhihong Chen and colleagues from Chengde Medical ... Akt signaling, decrease heme oxygenase-1 expression in the ... of hippocampal neurons in diabetic rats, thus protecting ... the growth hormone/insulin-like growth factor 1 axis undergoes ...
... taken part in an international study which has discovered a ... of a region. And the secret lies in crushed ... been spent by researchers gathering, classifying and recording insects and ... region. Any changes to the biodiversity of that area could ...
... Control, Automation and Electrical Systems , a new journal in ... as Controle and Automao , the new journal will ... available on Springer,s online platform, SpringerLink . ... covers industrial automation, addressing such topics as circuits and systems; ...
Cached Biology News:Insect 'soup' serving up rapid biodiversity monitoring 2Journal of Control, Automation and Electrical Systems now published by Springer 2
Taq DNA polymerase, 10,000U...
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
... a versatile and easy-to use enzyme, with ... Taq DNA Polymerase is prepared from a ... the DNA polymerase I gene from Thermococcus ... 5'-3' DNA polymerase activity. Its inherent 3'-5' ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: